An interventional study of Breakfast in Glucose Metabolism Disorders, sponsored by St. Mary's University, Twickenham. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 48 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by St. Mary's University, Twickenham · Not applicable, Interventional, and Basic science
The risk version of the MTNR1B gene (which codes for a melatonin receptor) has been associated with type II diabetes (T2D) and associated physiological markers. People with the risk version of the gene have reduced secretion of insulin when melatonin levels are high (between evening and morning) and impaired glucose tolerance when they eat late. Previous research suggests eating a protein enriched breakfast can improve glucose response. Therefore, the present study will investigate if the version of the MTNR1B gene that people have is associated with their glucose response after breakfast. Also, whether a protein enriched breakfast improves glucose response in participants with the risk version of the gene. Measures of glucose response collected over the two-week duration of the study will be compared between groups with the different versions of the gene. These findings can be used to provide personalised nutrition advice which may reduce the risk of T2D.
997 studies on the registry are indexed under Metabolic Diseases; 234 are open to participants now.
This study's enrollment of 60 is above the median of 48 across 670 interventional studies indexed under Metabolic Diseases.
Browse Metabolic Diseases studies →St. Mary's University, Twickenham is the lead sponsor of 16 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Dietary Supplement: Breakfast
Dietary Supplement: Breakfast
Breakfast in one condition will be high carbohydrate and in the other protein enriched
Glucose response
Area under the curve
Time frame: 120 minutes
CGM metrics - mean glucose
mean glucose for 14 days measured using (FreeStyle Libre Pro iQ Continuous Glucose Monitoring System)
Time frame: 14 days
CGM metrics - Time in range
Time in range for 14 day period (FreeStyle Libre Pro iQ Continuous Glucose Monitoring System)
Time frame: 14 days
CGM metrics - glycaemic variability
glycaemic variability for 14 day period (FreeStyle Libre Pro iQ Continuous Glucose Monitoring System)
Time frame: 14 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St. Mary's University, Twickenham